Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)

No abstract is available for this paper.

• Publication year

  1994

• Venue

  European Journal of Clinical Investigation

• Publication date

  1994-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2362.1994.tb02373.xPMID 7957500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries

  2005cited by this paper
• Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.

  1993cited by this paper
• Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.

  1992cited by this paper
• Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.

  1991cited by this paper
• Göttinger Risiko-, Inzidenz- und Prävalenzstudie (GRIPS)

  1991cited by this paper
• Lipoprotein (a): The link between impaired fibrinolysis and atherosclerosis

  1991cited by this paper
• Lipoprotein (a). Heterogeneity and biological relevance.

  1990cited by this paper
• Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

  1990cited by this paper
• Plasma fibrinogen — an independent cardiovascular risk factor

  1990cited by this paper
• A potential basis for the thrombotic risks associated with lipoprotein(a)

  1989cited by this paper
• Atherosclerosis and the coagulation system

  1989cited by this paper
• The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collabaration

  1988cited by this paper
• The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators.

  1988cited by this paper
• The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international Collaboration

  1988cited by this paper
• Incidence rates of fatal and nonfatal myocardial infarction in relation to the lipoprotein profile: first prospective results from the Göttingen Risk, Incidence, and Prevalence Study (GRIPS).

  1988cited by this paper
• Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study.

  1987cited by this paper
• cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

  1987cited by this paper
• Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

  1986cited by this paper
• Lipoprotein(a) as a strong indicator for cerebrovascular disease.

  1986cited by this paper
• Lp(a) lipoprotein as a risk factor for myocardial infarction.

  1986cited by this paper
• Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial.

  1986cited by this paper
• The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

  1986cited by this paper
• Risk factors for stroke.

  1985cited by this paper
• Isolation of apolipoprotein(a) from lipoprotein(a).

  1985cited by this paper
• Lipid Research Clinics Coronary Primary Prevention Trial results.

  1985cited by this paper
• Risk Factors for Stroke

  1985cited by this paper
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

  1984cited by this paper
• Optimal resources for primary prevention of atherosclerotic diseases. Atherosclerosis Study Group.

  1984cited by this paper
• Fibrinogen as a risk factor for stroke and myocardial infarction.

  1984cited by this paper
• Book-Review - Contact with the Stars - the Search for Extraterrestrial Life

  1982cited by this paper
• Lipoprotein Lp(a) and the risk for myocardial infarction.

  1981cited by this paper
• Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease.

  1980cited by this paper
• Intermittent claudication: prevalence and risk factors.

  1978cited by this paper
• The Electrocardiogram in Population Studies: A Classification System

  1960cited by this paper
• The Advanced Theory of Statistics

  1943cited by this paper
• CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography

  year unknowncited by this paper

• The yielding behaviour of human blood: A historical perspective to origins, measurements and clinical applications.

  2025cites this paper
• The influence of triglyceride and low-density-lipoprotein target levels on microcirculation: Is there a difference?

  2024cites this paper
• Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?

  2023cites this paper
• Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease

  2023cites this paper
• The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target.

  2022cites this paper
• Mental health is correlated with lipoprotein(a) levels in male patients with premature coronary heart disease.

  2021cites this paper
• Association of fibrinogen and D‑dimer levels with severity of acute coronary syndromes

  2021cites this paper
• Cardiovascular disease-related risk factors in perimenopausal women

  2020cites this paper
• Fibrinogen Diagnostics in Major Hemorrhage

  2020cites this paper
• Evaluation of coagulation parameters in patients with parathyroid adenoma

  2020cites this paper
• Quantifying Apolipoprotein(a) in the era of Proteoforms and Precision Medicine.

  2020cites this paper
• A SHORT STUDY ON THE CLINICO PATHOLOGICAL CORRELATION OF SERUM HOMOCYSTEINE LEVEL

  2020cites this paper
• Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.

  2019cites this paper
• Effect of Apheresis on Thrombotic Markers

  2019cites this paper
• Lipoprotein(a): the underutilized risk factor for cardiovascular disease

  2019cites this paper
• Wheat Flour, Enriched with γ-Oryzanol, Phytosterol, and Ferulic Acid, Alleviates Lipid and Glucose Metabolism in High-Fat-Fructose-Fed Rats

  2019cites this paper
• Lipid Disorders and Familial Hypercholesterolaemia

  2019cites this paper
• Cardiovascular risk factors in patients with premature cardiovascular events attending the University of Dresden Lipid Clinic.

  2019cites this paper
• Can Lipoprotein Apheresis Offer a Therapeutic Role in the Management of Patients With Refractory Angina and Raised Lipoprotein(a)?

  2018cites this paper
• Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial

  2017cites this paper
• Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

  2017cites this paper
• Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance

  2016cites this paper
• Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation.

  2016cites this paper
• Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

  2016cites this paper
• HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?

  2016cites this paper
• The relationship between Lp(a) and CVD outcomes: a systematic review

  2016cites this paper
• A Review Based Study on Risk factors for Coronary Heart Disease

  2015cites this paper
• Relationship between serum endothelin-1 level and spontaneous reperfusion in patients with acute myocardial infarction

  2015cites this paper
• Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease

  2015cites this paper
• The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.

  2015cites this paper
• Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.

  2015cites this paper
• Effects of Upstream Administration of Tirofiban Before Percutaneous Coronary Intervention on Spontaneous Reperfusion and Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction

  2015influential citation
• An elevated lipoprotein(a) plasma level as a cardiovascular risk factor.

  2015cites this paper
• ET-1 System Activity, Cardiovascular Disease Risk Factors and Pharmacologic Intervention

  2015cites this paper
• Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation

  2015cites this paper
• High prevalence of raised lipoprotein(a) in patients with refractory angina

  2015cites this paper
• Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients.

  2014cites this paper
• No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects

  2014cites this paper
• The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina

  2014cites this paper
• Endothelin-1 system activity in adults with borderline high ldl-cholesterol

  2014cites this paper
• Evidence for a Threshold Effect Impact of Apo(a) Length Polymorphism and the Control of Plasma Lp(a) Concentrations

  2013cites this paper
• Direct comparisons of three alternative plasma fibrinogen assays with the von Clauss assay in prediction of cardiovascular disease and all‐causes mortality: the Scottish Heart Health Extended Cohort

  2013cites this paper
• A Case Control study of Lipoprotein a levels in patients with Atherosclerotic Peripheral Arterial Occlusive disease

  2013cites this paper
• Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease

  2013cites this paper
• Between Circulating Fibrinogen and Cardiovascular Disease Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects

  2013cites this paper
• Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications

  2012cites this paper
• realizado en familiares de primer y segundo grado de pacientes con infarto agudo de miocardio.

  2012cites this paper
• Micronised Fenofibrate

  2012cites this paper
• Lipoprotein (a) and risk of cardiovascular disease--a systematic review and meta analysis of prospective studies.

  2011cites this paper
• Role of homocysteine and lipoprotein (A) in atherosclerosis: An update

  2011cites this paper
• patients with chronic stable angina pectoris Elevated plasma lipoprotein(a) is associated with coronary artery disease in

  2011cites this paper
• Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!

  2010cites this paper
• Influencia de la concentración de la lipoproteína(a) en la consecución de objetivos terapéuticos de colesterol LDL en pacientes de alto riesgo cardiovascular. Importancia del colesterol LDL corregido

  2010cites this paper
• Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy

  2010cites this paper
• Coronary heart disease.

  2010cites this paper
• Enigmatic Role of Lipoprotein(a) in Cardiovascular Disease

  2010cites this paper
• Is fibrinogen a marker of inflammation in coronary artery disease?

  2010cites this paper
• Is Fibrinogen a Marker of Inflammation in Coronary Artery Disease

  2010cites this paper
• Screening for Intermediate Risk Factors for Coronary Heart Disease

  2009cites this paper
• LIPID, HEMOSTATIC AND INFLAMMATORY MARKERS OF ATHEROTHROMBOTIC RISK

  2009cites this paper
• Cardiovascular events in patients with increased lipoprotein (a) - retrospective data analysis in an outpatient department of lipid disorders.

  2009cites this paper
• Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

  2009cites this paper
• Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients With Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging

  2009cites this paper
• Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II

  2008cites this paper
• Serial intravascular ultrasound assessment of coronary atherosclerosis progression and remodeling

  2008cites this paper
• The role of fibrinogen and fibrinolysis in peripheral arterial disease.

  2008cites this paper
• Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris.

  2008cites this paper
• Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data.

  2008cites this paper
• Lipoprotein(a) – Structure, Epidemiology, Function and Diagnostics of a Cardiovascular Risk Marker

  2008cites this paper
• Fibrinogen concentration: A marker of cardiovascular disorders in Nigerians.

  2007cites this paper
• Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk

  2007cites this paper
• The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases

  2007cites this paper
• in press-uncorrected proof Stoffwechsel Redaktion : W . März Lipoprotein ( a ) – Struktur , Epidemiologie und Funktion Lipoprotein ( a ) – structure , epidemiology and function

  2007cites this paper
• Lipoprotein(a): a unique risk factor for cardiovascular disease.

  2006cites this paper
• [Aortic stenosis and coronary disease. Analysis of risk factors].

  2006cites this paper
• Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals.

  2006cites this paper
• Increased serum levels of lipoprotein(a) correlated with the severity of coronary artery disease in patients submitted to angiography.

  2006cites this paper
• Elevated lipoprotein(a)--a genetic risk factor for premature vascular disease in people with and without standard risk factors: a review.

  2006cites this paper
• Dopplersonographische Messung der zerebralen Reservekapazität bei Patienten mit HELP Lipid Plasmapherese

  2006cites this paper
• Gap analysis of pediatric reference intervals for risk biomarkers of cardiovascular disease and the metabolic syndrome.

  2006cites this paper
• Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population.

  2006cites this paper
• Níveis plasmáticos elevados de lipoproteína(a) correlacionados com a gravidade da doença arterial coronariana em pacientes submetidos à angiografia

  2006cites this paper
• Pathophysiology of plasma lipids

  2006cites this paper
• Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial

  2006cites this paper
• Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries.

  2006cites this paper
• Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk

  2006cites this paper
• Fibrinógeno: ¿Factor o indicador de riesgo cardiovascular?

  2006cites this paper
• Concentraciones elevadas de lipoproteína(a) en plasma en pacientes psiquiátricos: una posible contribución al aumento del riesgo vascular

  2006cites this paper
• Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER).

  2005cites this paper
• Novel serologic markers of cardiovascular risk

  2005cites this paper
• Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke

  2005cites this paper
• Evaluation of Methods for the Measurement of Low-Density Lipoprotein Cholesterol

  2005cites this paper
• Conditional risk factors for atherosclerosis.

  2005cites this paper
• Platelet reactivity, polymorphisms and premature myocardial infarction

  2005influential citation
• Genetic Polymorphisms and Response to HMG-CoA Reductase Inhibitors

  2005cites this paper
• [Genetic aspects of individual sensitivity to statins].

  2005cites this paper
• Mulficenfer Study of Lipoprotein(a) and Apolipoprotein(a) Phenotypes in Patients With End-Stage Renal Disease Treated by Hemodialysis or Continuous Ambulatory Peritoneal Dialysis1

  2005cites this paper
• Effect of Fibrate on Lipoprotein(a) Level in Hypertriglyceridemic Patients

  2005cites this paper
• A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C‐reactive protein following myocardial infarction: the CADET trial

  2004cites this paper
• Diet and Plasma Lipoproteins in Elderly With and Without Cardiovascular Disease: Results From the Framingham Heart Study

  2004cites this paper